Trial Profile
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 14 Feb 2020 Planned End Date changed from 1 May 2020 to 1 May 2021.
- 14 Feb 2020 Planned primary completion date changed from 1 May 2019 to 1 May 2021.
- 12 Sep 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.